About PT-141 Medicine

What this site is

PT-141 Medicine is an independent editorial project that publishes plain-English summaries of the peer-reviewed research literature on PT-141 (bremelanotide). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The word "medicine" in our name describes the subject we cover — a medicine that has been studied and approved — and the editorial stance we take toward the literature. It is not a claim that this site offers treatment, consultation, prescriptions, or any clinical service. We occupy a reader's position relative to the research, nothing more.

How we work

Every quantitative claim on this site — every dose, percentage, effect size, half-life, and trial result — is tied to a numbered source on our references page, drawn from PubMed-indexed studies, the FDA prescribing information, and recognized monographs. We lead with what was measured and attribute it to its source. We separate three things readers often blur: what controlled trials found, what the approved label permits, and what the research-use community reports anecdotally. We keep those distinct on purpose.

What we are careful about

PT-141 (bremelanotide) is FDA-approved only for hypoactive sexual desire disorder in premenopausal women; we label every other use as off-label or investigational, because that is what the regulatory record shows. We recommend no dose to any individual and we name no commercial brands in our prose. Where the evidence is disputed — small effect sizes, a study under an Expression of Concern, debate over the diagnosis itself — we say so rather than smoothing it over. Honest framing is the whole point of the project.